To evaluate the clinical response, duration of analgesic effect, and safety profile of intravenous Lidocaine for refractory trigeminal neuralgia (TGN) in a retrospective case series and systematic review.
Key Findings:
Twenty patients were included in the case series, all with refractory TGN.
Lidocaine infusion provided symptomatic relief in patients unresponsive to standard treatments, with an average pain relief duration of X months (insert specific data).
Pain relief duration categorized into 6 months, with specific percentages (insert data).
Interpretation:
Intravenous Lidocaine may serve as an effective rescue therapy for patients with refractory TGN, especially when conventional treatments fail, highlighting its potential role in pain management strategies.
Limitations:
Retrospective design limits causal inference and may introduce selection bias.
Small sample size may affect generalizability.
Methodological heterogeneity in included studies for systematic review.
Conclusion:
Intravenous Lidocaine infusion shows promise as a treatment option for refractory TGN, warranting further investigation in larger, controlled studies to validate these findings.
